Researchers are modifying T-cell dose escalation and have introduced the prompt use of inhibitors that block the effects of IL-6 (tocilizumab or siltuximab) or TNF-α (Infliximab) to reduce the severity of CRS effects [237, 238]. This evidence concerns the gene TNF and congenital rubella syndrome.